dedicated to driving psychedelic research,
education and innovation forward.
PsyTech Discovery identifies impactful innovation and takes equity positions in select companies. PsyTech joins other ventures to provide bespoke incubation assistance through investment, research, development and growth. Ventures of interest include clinical trial services, educational courses, dosage and delivery technology, supply-chain solutions, and business and clinical data intelligence.
THE TEAM IS BEGINNING DEVELOPMENT ON TWO INITIAL VENTURES:
Ketamine Assisted Therapy (KAT) Clinical Protocol Study
PsyTech Discovery’s first venture will consist of supporting a Ketamine clinic in demonstrating the value of their proprietary protocol. The post-market KAT study will be done in conjunction with a U.S.-based clinic and an accredited academic instiution, which will drive a business venture educating physicians on KAT.
Psychedelic Medicine Online Courses
Through partnerships, PsyTech Discovery will create and distribute the highest-quality educational material for our community and the general public. With legalization, new markets will emerge and need certification; we will be ready when and where that happens.